MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, net of...
$134,771K
Proceeds from exercise of
stock options
$6,280K
Proceeds from sale of
common stock under...
$2,337K
Net cash provided by
financing activities
$143,388K
Net increase
(decrease) in cash, cash...
$88,822K
Canceled cashflow
$54,566K
Proceeds from sales and
maturities of marketable...
$361,800K
Other accrued
liabilities
$45,389K
Stock-based compensation
$41,720K
Accounts payable
$6,906K
Accrued payroll and
benefits
$1,956K
Prepaid expenses
-$1,716K
Amortization of intangible
assets
$961K
Depreciation
$855K
Non-cash lease expense
$682K
Amortization/accretion of debt-related
costs
$593K
Net cash (used in)
provided by investing...
-$42,115K
Net cash used in
operating activities
-$12,451K
Canceled cashflow
$361,800K
Canceled cashflow
$100,778K
Purchases of marketable
securities
$393,186K
Net loss
-$66,418K
Purchases of property and
equipment
$9,859K
Purchases of long-term
investments
$870K
Accounts receivable, net
$38,297K
Net
amortization/accretion on marketable...
$5,482K
Inventory
$1,751K
Other receivables
$754K
Other non-current
assets
$527K
Back
Back
Cash Flow
source: myfinsight.com
Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (TARS)